Cancer Immunology, Immunotherapy, Holger N. Lode et al. (submitted in 2012).

Suppl. Table 1
Primer sequences used for amplification of variable heavy (VH) and light (VL) chain regions of ganglidiomab.

Primer	*Sequence 5' → 3'*
	VH constant region
IgG1	ATAGACAGATGGGGGTGTCGTTTTGGC
	FR1 region VH
MH1	SARGTNMAGCTGSAGSAGTC
MH2	SARGTNMAGCTGSAGSAGTCWGG
MH3	CAGGTTACTCTGAAAGWGTSTG
MH4	GAGGTCCARCTGCAACARTC
MH5	CAGGTCCAACTVCAGCARCC
MH6	GAGGTGAASSTGGTGGAATC
MH7	GATGTGAACTTGGAAGTGTC
	VL κ constant region
Kc	GGATACAGTTGGTGCAGCATC
	FR1 region κ-light chain
Mk	GAYATTGTGMTSACMCARWCTMCA
	J-sequence VH
RPHJ	gctagcTGAGGAGACGGTGACTGAGGTTCC
	Leadersequence VH
MHALT1.RV	gaattc**cacc**ATGGRATGSAGCTGKGTMATSCTCTT
MHALT2.RV	gaattc**cacc**ATGRACTTCGGGYTGAGCTKGGTTTT
MHALT3.RV	gaattc**cacc**ATGGCTGTCTTGGGGCTGCTCTTCT
MHALT4.RV	gaattc**cacc**ATGGRCAGRCTTACWTYY
	J-sequence VL
RPLJ	gcagatgctgcAGCCCGTTTGATTTCCAGCTTGGTG
	Leadersequence VL κ
MLALT1.RV	ctcgag**cacc**ATGGAGACAGACACACTCCTGCTAT
MLALT2.RV	ctcgag**cacc**ATGGATTTTCAGGTGCAGATTTTCAG
MLALT3.RV	ctcgag**cacc**ATGRAGTCACAKACYCAGGTCTTYRTA
MLALT4.RV	ctcgag**cacc**ATGAGGKCCCCWGCTCAGYTYCTKGGR
MLALT5.RV	ctcgag**cacc**ATGAAGTTGCCTGTTAGGCTGTTG
MLALT6.RV	ctcgag**cacc**ATGATGAGTCCTGCCCAGTTCC

Restriction sites *Nhe*I (GCT AGC), *Eco*RI (GAA TTC), *Xho*I (CTC GAG) and *Bst*API (GCA NNNNN TGC) (underlined) and Kozak-sequence (bold) are indicated.

Suppl. Table 2. Screening results after 5 rounds of subcloning of the primary hybridoma cell culture.

Material tested	ch14.18[†]	hu14.18[†]
Supernatant clone 17[§]	1.068 ± 0.052	0.631 ± 0.020
Supernatant clone 17-9[§]	N.D.	1.490 ± 0.022
Supernatant clone 17-9-1[§]	1.851 ± 0.048	1.988 ± 0.091
Supernatant clone 17-9-1-1[‡]	N.D.	1.441 ± 0.008
Supernatant clone 17-9-1-5[‡]	N.D.	1.427 ± 0.010
Supernatant clone 17-9-1-1-12[‡]	N.D.	0.683 ± 0.025
Serum of immunized mice[&]	0.261 ± 0.038	0.192 ± 0.014
Negative control[#]	0.005 ± 0.001	0.001 ± 0.001

The supernatant of clone 17 (50 µl) was used undiluted[§] and diluted[‡] (1:200; PBS, pH 7.4) in the screening ELISA using ch14.18 and hu14.18 as a capture antigen, respectively.

[&]Serum of immunized mice was used after dilution of 1:100 in PBS.

[#]Cell culture supernatant of Sp2/0 cells was used as negative control

[†]Data represent MV ± SD of OD 405 readings